**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hrych  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

- 277** Patient global assessment to define remission in rheumatoid arthritis: quo vadis?  
*M Boers*

**Review**

- 280** Use of multidimensional composite scores in rheumatology: parsimony versus subtlety  
*R B M Landewé, D van der Heijde*

**Rheumatoid arthritis**

- 286** Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015  
*B R England, P Roul, Y Yang, H Sayles, F Yu, K Michaud, F Xie, J R Curtis, T R Mikuls*
- 293** Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients  
*R J O Ferreira, P M J Welsing, J W G Jacobs, L Gossec, M Ndosí, P M Machado, D van der Heijde, J A P Da Silva*

- 304** Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

*S B Cohen, R F van Vollenhoven, K L Winthrop, C A F Zerbini, Y Tanaka, L Bessette, Y Zhang, N Khan, B Hendrickson, J V Enejsa, G R Burmester*

**Psoriatic arthritis**

- 312** Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2  
*P J Mease, A Lerratanakul, J K Anderson, K Papp, F Van den Bosch, S Tsuji, E Dokoupilova, M Keiserman, X Wang, S Zhong, R M McCaskill, P Zueger, A L Pangan, W Tillett*

**Paediatric rheumatology**

- 321** Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms  
*E López-Isac, S L Smith, M C Marion, A Wood, M Sudman, A Yarwood, C Shi, V P Gaddi, P Martin, S Prahalad, S Eyre, G Orozco, A P Morris, C D Langefeld, S D Thompson, W Thomson, J Bowes*

**Sjögren's syndrome**

- 329** Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial  
*R Felten, V Devauchelle-Pensec, R Seror, P Duffau, D Saadoun, E Hachulla, H Pierre Yves, C Salliot, A Perdriger, J Morel, A Mékinian, O Vittecoq, J-M Berthelot, E Dennis, V Le Guem, P Dieudé, C Larroche, C Richez, T Marin, C Zamitsky, G Blaison, P Kieffer, F Maurier, A Dellal, S Rist, E Andres, A Contis, E Chatelus, C Sordet, J Sibilia, C Arnold, M Y Tawke, O Aberkane, L Holterbach, P Cacoub, A Saraux, X Mariette, N Meyer, J-E Gottenberg*

- 339** Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial  
*A N Baer, J-E Gottenberg, E W St Clair, T Sumida, T Takeuchi, R Seror, G Foulkes, M Nys, S Mukherjee, R Wong, N Ray, H Bootsma*

**Osteoarthritis**

- 349** Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial  
*P Richette, A Latourte, J Sellam, D Wendling, M Piperno, P Goupille, Y-M Pers, F Eymard, S Ottaviani, P Ornetti, R-M Flipo, B Fautrel, O Peyr, J P Bertola, E Vicaut, X Chevalier*

- 356** Precise targeting of miR-141/200c cluster in chondrocytes attenuates osteoarthritis development  
*M-L Ji, H Jiang, F Wu, R Geng, L Kun Ya, Y C Lin, J H Xu, X T Wu, J Lu*

- 367** Genome-wide association of phenotypes based on clustering patterns of hand osteoarthritis identify *WNT9A* as novel osteoarthritis gene  
*C G Boer, M S Yau, S J Rice, R Coutinho de Almeida, K Cheung, U Styrkarsdottir, L Southam, L Broer, J M Wilkinson, A G Uitterlinden, E Zeggini, D Felson, J Loughlin, M Young, T D Capellini, I Meulenbelt, J B J van Meurs*

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>




Member since 2008  
J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>




When you have finished with this please recycle it

- 376** OATargets: a knowledge base of genes associated with osteoarthritis joint damage in animals  
 *J Soul, M J Barter, C B Little, D A Young*

## Epidemiology

- 384** Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis  
*S Akiyama, S Hamdeh, D Micic, A Sakuraba*
- 392** High frequency of variants in genes associated with primary immunodeficiencies in patients with rheumatic diseases with secondary hypogammaglobulinaemia  
*G Sogkas, N Dubrowskaja, I R Adriawan, M Anim, T Witte, R E Schmidt, F Atscheckzei*

## Letters

- 401** COVID-19 and how evidence of a new disease evolves  
*F P B Kroon, T R Mikuls, R BM Landewé*
- 402** High oligoclonality of immunoglobulins in SARS-CoV2 positive patients  
*M Kolopp-Sarda, P Miossec*
- 403** Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia: a nationwide population-based cohort study  
*H-Y Mo, J C C Wei, X-H Chen, H-H Chen*
- 404** Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis  
 *S Yavuz, M Bianchi, S Kozyrev, K Bolin, D Leonard, P Pucholt, J K Sandling, A Bengtsson, A Jönsen, S Rantapää-Dahlqvist, C Sjöwall, E Svenungsson, I Gunnarsson, K Lindblad-Toh, L Rönnblom*
- 406** Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis  
*H Kim, S Dill, M O'Brien, L Vian, X Li, M Manukyan, M Jain, L W Adejo, J George, M Perez, A A Grom, M Sutter, B M Feldman, L Yao, M Millwood, A Brundidge, D C Pichard, E W Cowen, Y Shi, S Lu, W L Tsai, M Gadina, L G Rider, R A Colbert*

## Electronic pages

- e29** Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?  
*G L Erre, E S Ferraccioli, M Piga, A Mangoni, G Passiu, E Gremese, G Ferraccioli*

- e30** Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre *et al*  
*E R Graef, J W Liew, A HJ Kim, J A Sparks*
- e31** Hydroxychloroquine shortages during the COVID-19 pandemic  
*A Mendel, S Bernatsky, J C Thorne, D Lacaille, S R Johnson, É Vinet*
- e32** Response to: 'Hydroxychloroquine shortages during the COVID-19 pandemic' by Mendel *et al*  
*I McInnes*
- e33** Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'  
*M Nikpour, B Teh, I P Wicks, M Pellegrini*
- e34** Response to: 'Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour *et al*  
*A Mathian, Z Amoura*
- e35** Patients with lupus with COVID-19: University of Michigan experience  
*B Wallace, L Washer, W Marder, J M Kahlenberg*
- e36** Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace *et al*  
*A Mathian, Z Amoura*
- e37** Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab  
*J Avouac, P Airó, N Carlier, M Matucci-Cerinic, Y Allanore*
- e38** Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac *et al*  
*P Guilpain, C Le Bihan, V Foulongne, P Taourel, N Pansu, A T J Maria, B Jung, R Larcher, K Klouche, V Le Moing*
- e39** COVID-19 infection in a patient with FMF: does colchicine have a protective effect?  
*S Kobak*
- e40** Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak  
*S Monti, C Montecucco*

- e41** COVID-19 and Behçet's disease: clinical case series  
*G Espinosa, O Araujo, S Amaro, M Bodro, P J Moreno, R Moreno, A Ugarte, R Cervera*
- e42** Myositis as a manifestation of SARS-CoV-2  
*M Beydon, K Chevalier, O Al Tabaa, S Hamroun, A-S Delette, M Thomas, J Herrou, E Riviere, X Mariette*
- e43** Rheumatic disease and COVID-19  
*J W Liew, E R Graef*
- e44** COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy  
*S Benoy, R Traksel, P Verhaegh, J Broen*
- e45** Correction: Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial